Enable Injections
PrivateLast Round
Strategic
Jan 6, 2026
Est. Valuation
$930M
Total Funding Raised
$352M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Enable Injections is a medical device company that develops and manufactures wearable drug delivery systems for the subcutaneous self-administration of high-volume therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enable Injections Comparables
Compare Enable Injections with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nemera | 89% | |
| LTS Lohmann Therapie-Systeme AG | 89% | |
| Ypsomed Holding AG | 84% |
Enable Injections Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jan 6, 2026 | ||||
| Series C | Jan 27, 2022 | ||||
| Debt | Sep 8, 2020 | ||||
| Series B | Oct 25, 2018 | ||||
| Series A | Oct 5, 2016 | ||||
Seed | Sep 18, 2014 |
Key People
Founding team and executive leadership
Matthew Huddleston
Chief Commercial Officer, Executive Vice President & Chief Technology Officer
Enable Injections Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Magnetar Capital | Series C |
| Partisan Management Group | Series B |
| Squarepoint Ventures | Series C |
| CincyTech | Seed, Series A, Series B, Series C |
| GCM Grosvenor | Series C |
| ORI Capital | Series B, Series A |
| Oxford Finance | Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 43% MoM.
- Apr 9, 2026
Developing a digital companion solution for enFuse with Aptar Digital Health.
Enable Injections Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enable Injections's valuation, stock price, and market status.
Is Enable Injections a public or private company?
Enable Injections is a private company.
What is the current stock price of Enable Injections?
Enable Injections is a private company, so its shares have no public market price. Caplight tracks Enable Injections's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enable Injections worth (valuation)?
Enable Injections's valuation is estimated at $930.0M based on funding round data.
Can I buy Enable Injections stock?
Enable Injections shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enable Injections's last funding round?
Enable Injections's most recent funding round was Strategic on January 6, 2026.
Who are the main investors in Enable Injections?
Key investors in Enable Injections include Magnetar Capital, ORI Capital, Oxford Finance.
Will Enable Injections IPO soon?
No public IPO plans have been announced for Enable Injections.
How can I track Enable Injections secondary market activity?
Caplight tracks bids, offers, and trades in Enable Injections's shares on secondary markets.